Relay Therapeutics Inc.

Relay Therapeutics Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008 an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608 a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971 an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition it has collaboration and license agreements with D. E. Shaw Research LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery Inc. and changed its name to Relay Therapeutics Inc. in December 2015. Relay Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge Massachusetts.